Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 11/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7723573 | 0.92 | SLC6A9 (0.70) | SLC6A9 | |
| SCHEMBL7795137 | 0.89 | SLC6A9 (0.75) | SLC6A9POLBMAPTLMNATP53 | |
| SCHEMBL7795716 | 0.89 | SLC6A9 (0.60) | SLC6A9POLBMAPTLMNATP53 | |
| SCHEMBL2860502 | 0.86 | SLC6A9 (0.75) | SLC6A9POLBLMNATP53PKM | |
| SCHEMBL7801716 | 0.85 | SLC6A9 (0.76) | SLC6A9POLBLMNATP53 | |
| SCHEMBL7801289 | 0.84 | SLC6A9 (0.70) | SLC6A9POLBMAPTLMNATP53 | |
| SCHEMBL7795359 | 0.84 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL7795612 | 0.84 | SLC6A9 (0.88) | SLC6A9POLBLMNA | |
| SCHEMBL7801713 | 0.83 | SLC6A9 (0.81) | SLC6A9POLBLMNA | |
| SCHEMBL7720216 | 0.81 | SLC6A9 (0.69) | SLC6A9POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436019-B2 | Sulfonyl-piperidin-4-yl methylamine amide analogs as GlyT1 inhibitors, methods for making same, and use of same in treating psychiatric disorders | VANDERBILT UNIVERSITY (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436019-B2 | Sulfonyl-piperidin-4-yl methylamine amide analogs as GlyT1 inhibitors, methods for making same, and use of same in treating psychiatric disorders | VANDERBILT UNIVERSITY (US) | 2013-05-07 | — | — | US | disclosed |
| US-20100256186-A1 | SULFONYL-PIPERIDIN-4-YL METHYLAMINE AMIDE ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2010-10-07 | — | — | US | disclosed |
| US-20100256186-A1 | SULFONYL-PIPERIDIN-4-YL METHYLAMINE AMIDE ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2010-10-07 | — | — | US | disclosed |
| WO-2010114909-A1 | SULFONYL-PIPERIDIN-4-YL METHYLAMINE AMIDE ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256186-A1 | SULFONYL-PIPERIDIN-4-YL METHYLAMINE AMIDE ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | SLC1A2, SLC1A1, SLC18A2 | SLC6A9 22/4885POLB 4800/4885MAPT 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.